← Back to Search

Anti-tumor antibiotic

Cirmtuzumab Consolidation for Chronic Lymphocytic Leukemia (Venetoclax Trial)

Phase 2
Waitlist Available
Led By Benjamin M Heyman, MD
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who have discontinued venetoclax more than 6 months prior to study entry must still have a disease burden meeting criteria for low risk of TLS (i.e. no lymph node greater than 5 cm in diameter; absolute lymphocyte count less than 25 k/uL)
Must have detectable CLL/SLL (> 0.01% leukemia cells present)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9-24 months
Awards & highlights

Venetoclax Trial Summary

This trial is testing whether a drug called cirmtuzumab can help people with cancer who have responded to treatment with venetoclax.

Who is the study for?
This trial is for patients with chronic lymphocytic leukemia (CLL) who still have detectable disease after at least 12 months on venetoclax. They must not have significant uncontrolled conditions or infections, and women cannot be pregnant or breastfeeding. Those recently treated with certain therapies or having another malignancy may be excluded.Check my eligibility
What is being tested?
The study is testing the effectiveness of cirmtuzumab given to patients who are already taking venetoclax but still show signs of CLL. It's a phase 2 trial where all participants will receive cirmtuzumab to see if it can further reduce leukemia cells.See study design
What are the potential side effects?
Potential side effects include reactions related to the immune system, such as infusion reactions from cirmtuzumab, and those associated with venetoclax like low blood cell counts, fatigue, nausea, and risk of infection.

Venetoclax Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I stopped taking venetoclax over 6 months ago and my cancer is considered low risk.
Select...
My blood test shows more than 0.01% leukemia cells.
Select...
I am currently taking venetoclax.
Select...
I have been on venetoclax for at least 12 months.
Select...
I am currently taking venetoclax.

Venetoclax Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9-24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9-24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cancer response to treatment
Secondary outcome measures
Frequency of adverse events
Time to next CLL treatment.
Other outcome measures
Change in gene expression in leukemic cells

Venetoclax Trial Design

1Treatment groups
Experimental Treatment
Group I: Cirmtuzumab + VenetoclaxExperimental Treatment2 Interventions
All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venetoclax
2019
Completed Phase 3
~1990

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,114 Previous Clinical Trials
1,519,875 Total Patients Enrolled
Oncternal Therapeutics, IncIndustry Sponsor
6 Previous Clinical Trials
325 Total Patients Enrolled
Benjamin M Heyman, MDPrincipal InvestigatorUniversity of California, San Diego

Media Library

Venetoclax (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT04501939 — Phase 2
Chronic Lymphocytic Leukemia Research Study Groups: Cirmtuzumab + Venetoclax
Chronic Lymphocytic Leukemia Clinical Trial 2023: Venetoclax Highlights & Side Effects. Trial Name: NCT04501939 — Phase 2
Venetoclax (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04501939 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment efforts for this research ongoing at this time?

"That is accurate. The clinicaltrials.gov website has information indicating that this trial is actively recruiting patients. This specific study was first advertised on August 6th 2020 and updated November 24th 2021. Currently, the trial is looking for 16 individuals across 1 medical site."

Answered by AI

What are the odds of developing negative side effects from Cirmtuzumab?

"Cirmtuzumab falls into a Phase 2 category, which suggests that while there is data attesting to its safety, none has been collected regarding the medication's efficacy. Our team at Power rated it as a 2."

Answered by AI

Are there any similar past clinical trials that utilized Cirmtuzumab?

"Cirmtuzumab is being studied in 226 active clinical trials, 29 of which are Phase 3 studies. Most of the research on Cirmtuzumab is taking place in Boston, but there are 7269 total locations running trials for this medication."

Answered by AI

How many participants are being included in this research project?

"Yes, the trial is still accepting patients. According to the website, clinicaltrials.gov, the study was first posted on 8/6/2020 and updated as recently as 11/24/2021. Currently, they are looking for 16 more participants at 1 site."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
UCSD Koman Family Outpatient Pavilion
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. UCSD Koman Family Outpatient Pavilion: < 48 hours
Average response time
  • < 2 Days
~1 spots leftby Jul 2025